Vaxcyte, Inc.
Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update
VAX-31 Adult Indication: Announced Positive Topline Data from OPUS-1 Pivotal Phase 3 Trial; VAX-31 Met All Prespecified Primary Endpoints, Was Well…
Company newsroom
Vaxcyte, Inc.
NASDAQ:PCVX
1 releases